Published in Br J Pharmacol on January 01, 1985
Important role of mucosal serotonin in colonic propulsion and peristaltic reflexes: in vitro analyses in mice lacking tryptophan hydroxylase 1. J Physiol (2013) 1.25
Colonic migrating motor complexes, high amplitude propagating contractions, neural reflexes and the importance of neuronal and mucosal serotonin. J Neurogastroenterol Motil (2014) 1.00
Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theor Biol Med Model (2010) 0.93
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl) (2007) 0.88
An in vivo dialysis and behavioural study of the release of 5-HT by p-chloroamphetamine in reserpine-treated rats. Br J Pharmacol (1989) 0.88
The mechanism of tetrahydroaminoacridine-evoked release of endogenous 5-hydroxytryptamine and dopamine from rat brain tissue prisms. Br J Pharmacol (1989) 0.85
Concurrent determination of effects of p-chloroamphetamine on central extracellular 5-hydroxytryptamine concentration and behaviour. Br J Pharmacol (1989) 0.82
Activation and desensitization of presynaptic alpha 2-adrenoceptors after inhibition of neuronal uptake by antidepressant drugs in the rat vas deferens. Br J Pharmacol (1986) 0.82
Monoaminergic involvement in the pharmacological actions of buspirone. Br J Pharmacol (1985) 0.77
p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther (1966) 5.52
Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol Pharmacol (1976) 1.93
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur J Pharmacol (1976) 1.66
Antiamphetamine effects following inhibition of tyrosine hydroxylase. J Pharmacol Exp Ther (1966) 1.65
Tryptophan hydroxylase inhibition: the mechanism by which p-chlorophenylalanine depletes rat brain serotonin. Mol Pharmacol (1967) 1.62
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
An animal behavior model for studying central serotonergic synapses. Life Sci (1976) 1.47
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Actions of drugs that deplete serotonin. Fed Proc (1977) 1.24
Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther (1978) 1.16
Role of catecholamines in the amphetamine excitatory response. Nature (1966) 1.15
Brain tryptophan hydroxylase: purification of, production of antibodies to, and cellular and ultrastructural localization in serotonergic neurons of rat midbrain. Proc Natl Acad Sci U S A (1975) 1.08
The behavioural effects of RU 24969, a suggested 5-HT1 receptor agonist in rodents and the effect on the behaviour of treatment with antidepressants. Neuropharmacology (1984) 0.95
The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats. Naunyn Schmiedebergs Arch Pharmacol (1980) 0.93
The effect of inhibition of catecholamine synthesis on dexamphetamine induced central stimulation. Eur J Pharmacol (1970) 0.88
Effect of 3-(p-trifluoromethylphenoxy). N. N. methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine. J Pharmacol Exp Ther (1975) 0.87
Efflux of 5-hydroxytryptamine from synaptosomes of rat cerebral cortex. Acta Physiol Scand (1977) 0.87
Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker. Br J Pharmacol (1983) 0.83
Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones. Acta Pharmacol Toxicol (Copenh) (1977) 0.83
Evidence for the synthesis and storage of 5-hydroxytryptamine in two separate pools in the brain. J Neurochem (1973) 0.82
Loss of body weight as a predictor of reserpine-induced amine depletion. Eur J Pharmacol (1975) 0.82
Effect of d-amphetamine on spontaneous and stimulation-induced release of catecholamines. Acta Physiol Scand Suppl (1971) 0.82
Effect of apomorphine on behaviour induced by 5-methoxy-N, N-dimethyl tryptamine: three different scoring methods give three different conclusions. Psychopharmacology (Berl) (1983) 0.81
Regional differences in the response of serotonergic neurons in rat CNS to drugs. Eur J Pharmacol (1983) 0.80
The flux of radioactive label through components of the serotonergic system following the injection of [3H]tryptophan: product--precursor anomalies providing evidence that serotonin exists in multiple pools. J Neurochem (1978) 0.80
Model of brain serotonin metabolism. II. Physiological interpretation. Am J Physiol (1983) 0.80
p-Chloroamphetamine--inhibition of cerebral tryptophan hydroxylase. Biochem Pharmacol (1972) 0.78
Kinetic characteristics of newly synthesized 3H-5-HT in the brain of control and reserpinized mice. Evidence for the heterogeneous distribution of 5-HT in serotoninergic neurons. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.78
Subcellular distribution of 5-hydroxytryptamine in rat brain during development: effect of drugs and fasting. J Neurochem (1975) 0.77
Pharmacological studies on serotonin-mediated behaviour. J Physiol (Paris) (1981) 0.77
Simultaneous determination of 5-hydroxytryptamine, its amino acid precursors and acid metabolite in discrete brain regions by high-performance liquid chromatography with fluorescence detection. J Chromatogr (1983) 0.77
A fluorescence and electron microscopic study on central monoamine nerve cells. Anat Rec (1966) 0.77
L-Tryptophan administration potentiates serotonin-dependent myoclonic behavior in the rat. Neuropharmacology (1980) 0.76
Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol (2001) 6.98
Public and biobank participant attitudes toward genetic research participation and data sharing. Public Health Genomics (2010) 3.57
Assessing the understanding of biobank participants. Am J Med Genet A (2009) 3.04
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Properties of purified, soluble monoamine oxidase. Can J Biochem (1966) 1.76
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Multiple forms of human brain mitochondrial monoamine oxidase. Nature (1970) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Voriconazole -- better chances for patients with invasive mycoses. Eur J Med Res (2002) 1.59
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension (1980) 1.43
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem (2001) 1.30
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
An analysis of some discriminative properties of d-amphetamine. Psychopharmacologia (1974) 1.24
Effect of iron chelators on dopamine D2 receptors. J Neurochem (1985) 1.22
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine. Nature (1968) 1.19
The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol (2008) 1.19
Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl (1997) 1.16
A disconnection analysis of hippocampal function. Brain Res (1982) 1.15
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc Natl Acad Sci U S A (1985) 1.11
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature (1972) 1.09
The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase. Biochem Pharmacol (1975) 1.08
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Adv Biochem Psychopharmacol (1974) 1.07
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. Br J Pharmacol (1979) 1.07
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem (1996) 1.07
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Distribution, morphology, and neurochemistry of endocardial and epicardial nerve terminal arborizations in the human heart. Circulation (1995) 1.05
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem (1991) 1.04
Decreased monoamine oxidase activity in liver of iron-deficient rats. Can J Biochem (1969) 1.03
Mechanism of oxygen activation by tyrosine hydroxylase. Biochemistry (1987) 1.02
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem (2001) 1.01
Heterogeneity of rat brain mitochondrial monoamine oxidase. Adv Biochem Psychopharmacol (1974) 1.00
Immunohistochemical and ultrastructural localisation of peptide-containing nerves and myocardial cells in the human atrial appendage. Cell Tissue Res (1988) 0.99
The oestrous cycle and monoamine oxidase activity. Br J Pharmacol (1973) 0.99
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol (1981) 0.99
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
An immunocytochemical study of cutaneous innervation and the distribution of neuropeptides and protein gene product 9.5 in man and commonly employed laboratory animals. Am J Anat (1991) 0.98
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
Brain iron: a lesson from animal models. Am J Clin Nutr (1989) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism (1992) 0.97
Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol (1981) 0.96
Nutritional iron and dopamine binding sites in the rat brain. Pharmacol Biochem Behav (1982) 0.96
Tryptophan hydroxylase. The role of oxygen, iron, and sulfhydryl groups as determinants of stability and catalytic activity. J Biol Chem (1980) 0.96
Proceedings: Substrate and strain-dependent differences in the development of monoamine oxidase in the rat brain. Br J Pharmacol (1975) 0.96
Cell-type-specific rescue of myosin function during Dictyostelium development defines two distinct cell movements required for culmination. Development (1998) 0.95
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta (1996) 0.95
Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung. Br J Pharmacol (1976) 0.94
Tetrahydrobiopterin as a mediator of PC12 cell proliferation induced by EGF and NGF. Eur J Neurosci (1997) 0.94
Regulation of pheromone biosynthesis by a brain hormone in two moth species. Proc Natl Acad Sci U S A (1989) 0.94
Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem (1996) 0.93
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci (2000) 0.93
The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat. Eur J Pharmacol (1971) 0.93
Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther (1999) 0.93
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem (1991) 0.93
Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem (1995) 0.92
The influence of tissue environment on the rates of metabolic processes and the properties of enzymes. Biochem Pharmacol (1975) 0.92
Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl (2000) 0.91
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol (1987) 0.91
Estrogen desensitizes 5-HT(1A) receptors and reduces levels of G(z), G(i1) and G(i3) proteins in the hypothalamus. Neuropharmacology (2000) 0.90
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J Neurol (2000) 0.90
Pharmacology of selegiline. Neurology (1996) 0.90
Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. Int J Dev Neurosci (1986) 0.89
Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol (1993) 0.89
Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol (1999) 0.89
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl (1995) 0.89
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna) (2001) 0.89
Development of the peptidergic innervation of human heart. J Anat (1993) 0.88
Human platelet monoamine oxidase activity in iron-deficiency anaemia. Clin Sci Mol Med (1975) 0.88
L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiatry (1983) 0.88
Iron, melanin and dopamine interaction: relevance to Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry (1993) 0.88
The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats. Neuropharmacology (1980) 0.88
Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. Br J Pharmacol (1975) 0.88
Further properties of multiple forms of mitochondrial monoamine oxidase. Biochem J (1969) 0.87
Iron deficiency and neurotransmitter synthesis and function. Proc Nutr Soc (1978) 0.87
The reaction of bovine and rat liver monoamine oxidase with [14C]-clorgyline and [14C]-deprenyl. Mol Pharmacol (1979) 0.87
Multiple forms of mitochondrial monoamine oxidase. Br Med Bull (1973) 0.87
The flavin prosthetic group of purified rat liver mitochondrial monoamine oxidase. Adv Biochem Psychopharmacol (1972) 0.87
Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol (1992) 0.86
Inactivation of monoamines by the lung. Ciba Found Symp (1980) 0.86
Iron deficiency-induced circadian rhythm reversal of dopaminergic-mediated behaviours and thermoregulation in rats. Eur J Pharmacol (1981) 0.86